Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Intensive Care Medicine
Erschienen in: Intensive Care Medicine 2/2020

26.11.2019 | Narrative Review

Missed vaccinations and critical care admission: all you may wish to know or rediscover—a narrative review

verfasst von: Laure F. Pittet, Mohamed Abbas, Claire-Anne Siegrist, Didier Pittet

Erschienen in: Intensive Care Medicine | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Most vaccines are so effective that they could lead to the control/elimination of the diseases they target and directly impact on intensive care admissions or complications. This is best illustrated by the use of vaccines against Haemophilus influenzae type b, Streptococcus pneumoniae, zoster, yellow fever, Ebola virus, influenza or measles—but also by third party strategies such as maternal, toddler and care-giver immunization. However, each of these vaccine-induced protection is threatened by insufficient vaccine uptake. Here, we briefly discuss how vaccine hesitancy has led to the resurgence of diseases that were considered as controlled and explore the effect of vaccine-hesitant healthcare workers on nosocomial infections. As intensive care physicians are in charge of polymorbid patients, we briefly summarize the current recommendations for vaccinations in high-risk patients. We finally give some perspective on ongoing research, and discuss how institutional policies and intensive care physicians could play a role in increasing the impact of vaccination, overall and in intensive care units.
Literatur
1.
Plotkin SL, Plotkin SA (2018) A short history of vaccination. In: Plotkin SA, Orenstein WA, Offit PA, Edwards KM (eds) Plotkin’s vaccines. Elsevier, Philadelphia, pp 1–15
2.
Reisner-Senelar L (2011) The birth of intensive care medicine: Bjorn Ibsen’s records. Intensive Care Med 37:1084–1086PubMed
3.
Martinez M, Shukla H, Nikulin J, Mbaeyi C, Jorba J, Ehrhardt D (2019) Progress toward poliomyelitis eradication—Afghanistan, January 2018–May 2019. MMWR Morb Mortal Wkly Rep 68:729–733PubMedPubMedCentral
4.
Kyu HH, Mumford JE, Stanaway JD, Barber RM, Hancock JR, Vos T, Murray CJ, Naghavi M (2017) Mortality from tetanus between 1990 and 2015: findings from the global burden of disease study 2015. BMC Public Health 17:179PubMedPubMedCentral
5.
VanderEnde K, Gacic-Dobo M, Diallo MS, Conklin LM, Wallace AS (2018) Global routine vaccination coverage—2017. MMWR Morb Mortal Wkly Rep 67:1261–1264PubMedPubMedCentral
6.
Ortiz JR, Neuzil KM, Shay DK, Rue TC, Neradilek MB, Zhou H, Seymour CW, Hooper LG, Cheng PY, Goss CH, Cooke CR (2014) The burden of influenza-associated critical illness hospitalizations. Crit Care Med 42:2325–2332PubMedPubMedCentral
7.
Zhang QL, Wan CM, MacDonald NE (2009) Vaccine preventable infections and multiple organ dysfunction syndrome in critically ill children in China. Pediatr Infect Dis J 28:182–185PubMed
8.
Zhou F, Shefer A, Wenger J, Messonnier M, Wang LY, Lopez A, Moore M, Murphy TV, Cortese M, Rodewald L (2014) Economic evaluation of the routine childhood immunization program in the United States, 2009. Pediatrics 133:577–585PubMed
9.
Yu W, Lee LA, Liu Y, Scherpbier RW, Wen N, Zhang G, Zhu X, Ning G, Wang F, Li Y, Hao L, Zhang X, Wang H (2018) Vaccine-preventable disease control in the People’s Republic of China: 1949–2016. Vaccine 36:8131–8137PubMedPubMedCentral
10.
Offit PA (2005) The Cutter incident: how America’s first polio vaccine led to the growing vaccine crisis. Yale University Press, New Haven
11.
Wakefield AJ, Murch SH, Anthony A, Linnell J, Casson DM, Malik M, Berelowitz M, Dhillon AP, Thomson MA, Harvey P, Valentine A, Davies SE, Walker-Smith JA (1998) Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 351:637–641PubMed
12.
Peters A, Tartari E, Lotfinejad N, Parneix P, Pittet D (2018) Fighting the good fight: the fallout of fake news in infection prevention and why context matters. J Hosp Infect 100:365–370PubMed
13.
McClure CC, Cataldi JR, O’Leary ST (2017) Vaccine hesitancy: where we are and where we are going. Clin Ther 39:1550–1562PubMed
14.
Watt JP, Wolfson LJ, O’Brien KL, Henkle E, Deloria-Knoll M, McCall N, Lee E, Levine OS, Hajjeh R, Mulholland K, Cherian T (2009) Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: global estimates. Lancet 374:903–911PubMed
15.
Nanduri SA, Sutherland AR, Gordon LK, Santosham M (2018) Haemophilus influenzae type b vaccines. In: Plotkin SA, Orenstein WA, Offit PA, Edwards KM (eds) Plotkin’s vaccines. Elsevier, Philadelphia, pp 301–318
16.
Peltola H (2000) Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Rev 13:302–317PubMedPubMedCentral
17.
Hajjeh RA, Privor-Dumm L, Edmond K, O’Loughlin R, Shetty S, Griffiths UK, Bear AP, Cohen AL, Chandran A, Schuchat A, Mulholland EK, Santosham M (2010) Supporting new vaccine introduction decisions: lessons learned from the Hib Initiative experience. Vaccine 28:7123–7129PubMed
18.
Welte T, Torres A, Nathwani D (2012) Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax 67:71–79PubMed
19.
Drijkoningen JJ, Rohde GG (2014) Pneumococcal infection in adults: burden of disease. Clin Microbiol Infect 20(Suppl 5):45–51PubMed
20.
Wotton CJ, Goldacre MJ (2012) Risk of invasive pneumococcal disease in people admitted to hospital with selected immune-mediated diseases: record linkage cohort analyses. J Epidemiol Community Health 66:1177–1181PubMed
21.
Shea KM, Edelsberg J, Weycker D, Farkouh RA, Strutton DR, Pelton SI (2014) Rates of pneumococcal disease in adults with chronic medical conditions. Open Forum Infect Dis 1:ofu024PubMedPubMedCentral
22.
Garcia-Vidal C, Carratala J, Fernandez-Sabe N, Dorca J, Verdaguer R, Manresa F, Gudiol F (2009) Aetiology of, and risk factors for, recurrent community-acquired pneumonia. Clin Microbiol Infect 15:1033–1038PubMed
23.
Grau I, Ardanuy C, Cubero M, Benitez MA, Linares J, Pallares R (2016) Declining mortality from adult pneumococcal infections linked to children’s vaccination. J Infect 72:439–449PubMed
24.
Geno KA, Gilbert GL, Song JY, Skovsted IC, Klugman KP, Jones C, Konradsen HB, Nahm MH (2015) Pneumococcal capsules and their types: past, present, and future. Clin Microbiol Rev 28:871–899PubMedPubMedCentral
25.
Pittet LF, Posfay-Barbe KM (2012) Pneumococcal vaccines for children: a global public health priority. Clin Microbiol Infect 18(Suppl 5):25–36PubMed
26.
Borrow R, Heath PT, Siegrist CA (2012) Use of pneumococcal polysaccharide vaccine in children: what is the evidence? Curr Opin Infect Dis 25:292–303PubMed
27.
Jackson LA, Gurtman A, van Cleeff M, Jansen KU, Jayawardene D, Devlin C, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B (2013) Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. Vaccine 31:3577–3584PubMed
28.
Scott DA, Komjathy SF, Hu BT, Baker S, Supan LA, Monahan CA, Gruber W, Siber GR, Lockhart SP (2007) Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults. Vaccine 25:6164–6166PubMed
29.
Pilishvili T, Bennett NM (2015) Pneumococcal disease prevention among adults: strategies for the use of pneumococcal vaccines. Vaccine 33(Suppl 4):D60–D65PubMed
30.
Pittet LF, Verolet CM, Michetti P, Girardin M, Juillerat P, Mottet C, Maillard MH, Siegrist CA, Posfay-Barbe KM, Swiss Inflammatory Bowel Disease Cohort Study Group (2019) High immunogenicity of the pneumococcal conjugated vaccine in immunocompromised adults with inflammatory bowel disease. Am J Gastroenterol 114:1130–1141PubMed
31.
Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, van Werkhoven CH, van Deursen AM, Sanders EA, Verheij TJ, Patton M, McDonough A, Moradoghli-Haftvani A, Smith H, Mellelieu T, Pride MW, Crowther G, Schmoele-Thoma B, Scott DA, Jansen KU, Lobatto R, Oosterman B, Visser N, Caspers E, Smorenburg A, Emini EA, Gruber WC, Grobbee DE (2015) Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 372:1114–1125PubMed
32.
Castiglia P (2014) Recommendations for pneumococcal immunization outside routine childhood immunization programs in Western Europe. Adv Ther 31:1011–1044PubMedPubMedCentral
33.
Kim DK, Bridges CB, Harriman KH (2015) Advisory committee on immunization practices recommended immunization schedule for adults aged 19 years or older—United States, 2015. MMWR Morb Mortal Wkly Rep 64:91–92PubMedPubMedCentral
34.
Staples JE, Monath TP, Gershman MD, Barrett ADT (2018) Yellow fever vaccines. In: Plotkin SA, Orenstein WA, Offit PA, Edwards KM (eds) Plotkin’s vaccines. Elsevier, Philadelphia, pp 1181–1265
35.
World Health Organization (2018) A global strategy to eliminate yellow fever epidemics 2017–2026. World Health Organization, Geneva
36.
Casey RM, Harris JB, Ahuka-Mundeke S, Dixon MG, Kizito GM, Nsele PM, Umutesi G, Laven J, Kosoy O, Paluku G, Gueye AS, Hyde TB, Ewetola R, Sheria GKM, Muyembe-Tamfum J-J, Staples JE (2018) Immunogenicity of fractional-dose vaccine during a yellow fever outbreak—final report. N Engl J Med 381:444–454PubMedPubMedCentral
37.
Halperin SA, Bettinger JA, Greenwood B, Harrison LH, Jelfs J, Ladhani SN, McIntyre P, Ramsay ME, Safadi MA (2012) The changing and dynamic epidemiology of meningococcal disease. Vaccine 30(Suppl 2):B26–B36PubMed
38.
Ramsay ME, Andrews N, Kaczmarski EB, Miller E (2001) Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet 357:195–196PubMed
39.
40.
Mustapha MM, Harrison LH (2018) Vaccine prevention of meningococcal disease in Africa: major advances, remaining challenges. Hum Vaccines Immunother 14:1107–1115
41.
Bryan P, Seabroke S, Wong J, Donegan K, Webb E, Goldsmith C, Vipond C, Feavers I (2018) Safety of multicomponent meningococcal group B vaccine (4CMenB) in routine infant immunisation in the UK: a prospective surveillance study. Lancet Child Adolesc Health 2:395–403PubMed
42.
Parikh SR, Andrews NJ, Beebeejaun K, Campbell H, Ribeiro S, Ward C, White JM, Borrow R, Ramsay ME, Ladhani SN (2016) Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study. Lancet 388:2775–2782PubMed
43.
Kuhdari P, Stefanati A, Lupi S, Valente N, Gabutti G (2016) Meningococcal B vaccination: real-world experience and future perspectives. Pathog Glob Health 110:148–156PubMedPubMedCentral
44.
45.
World Health Organization (2010) Cholera vaccines: WHO position paper. Wkly Epidemiol Rec 85:117–128
46.
Global Task Force on Cholera Control (2017) Ending cholera—a global roadmap to 2030. World Health Organization, Geneva
47.
Ali M, Emch M, von Seidlein L, Yunus M, Sack DA, Rao M, Holmgren J, Clemens JD (2005) Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis. Lancet 366:44–49PubMed
48.
Longini IM Jr, Nizam A, Ali M, Yunus M, Shenvi N, Clemens JD (2007) Controlling endemic cholera with oral vaccines. PLoS Med 4:e336PubMedPubMedCentral
49.
Jeuland M, Cook J, Poulos C, Clemens J, Whittington D (2009) Cost-effectiveness of new-generation oral cholera vaccines: a multisite analysis. Value Health 12:899–908PubMed
50.
Higgs ES, Dubey SA, Coller BAG, Simon JK, Bollinger L, Sorenson RA, Wilson B, Nason MC, Hensley LE (2017) Accelerating vaccine development during the 2013–2016 West African Ebola virus disease outbreak. Curr Top Microbiol Immunol 411:229–261PubMed
51.
Agnandji ST, Huttner A, Zinser ME et al (2016) Phase 1 trials of rVSV Ebola vaccine in Africa and Europe. N Engl J Med 374:1647–1660PubMed
52.
Henao-Restrepo AM, Camacho A, Longini IM et al (2017) Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola ça suffit!). Lancet 389:505–518PubMedPubMedCentral
53.
Ilunga Kalenga O, Moeti M, Sparrow A, Nguyen VK, Lucey D, Ghebreyesus TA (2019) The ongoing Ebola epidemic in the Democratic Republic of Congo, 2018–2019. N Engl J Med 381:373–383PubMed
54.
Straney L, Schibler A, Ganeshalingham A, Alexander J, Festa M, Slater A, MacLaren G, Schlapbach LJ (2016) Burden and outcomes of severe pertussis infection in critically ill infants. Pediatr Crit Care Med 17:735–742PubMed
55.
Cherry JD (2012) Epidemic pertussis in 2012—the resurgence of a vaccine-preventable disease. N Engl J Med 367:785–787PubMed
56.
Esposito S, Stefanelli P, Fry NK, Fedele G, He Q, Paterson P, Tan T, Knuf M, Rodrigo C, Weil Olivier C, Flanagan KL, Hung I, Lutsar I, Edwards K, O’Ryan M, Principi N (2019) Pertussis prevention: reasons for resurgence, and differences in the current acellular pertussis vaccines. Front Immunol 10:1344PubMedPubMedCentral
57.
Wendelboe AM, Njamkepo E, Bourillon A, Floret DD, Gaudelus J, Gerber M, Grimprel E, Greenberg D, Halperin S, Liese J, Munoz-Rivas F, Teyssou R, Guiso N, Van Rie A (2007) Transmission of Bordetella pertussis to young infants. Pediatr Infect Dis J 26:293–299PubMed
58.
Lumbreras Areta M, Eberhardt CS, Siegrist CA, Martinez de Tejada B (2019) Antenatal vaccination to decrease pertussis in infants: safety, effectiveness, timing, and implementation. J Matern Fetal Neonatal Med 32:1541–1546PubMed
59.
Eberhardt CS, Blanchard-Rohner G, Lemaitre B, Boukrid M, Combescure C, Othenin-Girard V, Chilin A, Petre J, de Tejada BM, Siegrist CA (2016) Maternal immunization earlier in pregnancy maximizes antibody transfer and expected infant seropositivity against pertussis. Clin Infect Dis 62:829–836PubMedPubMedCentral
60.
Eberhardt CS, Blanchard-Rohner G, Lemaitre B, Combescure C, Othenin-Girard V, Chilin A, Petre J, Martinez de Tejada B, Siegrist CA (2017) Pertussis antibody transfer to preterm neonates after second- versus third-trimester maternal immunization. Clin Infect Dis 64:1129–1132PubMedPubMedCentral
61.
Sobanjo-Ter Meulen A, Duclos P, McIntyre P, Lewis KD, Van Damme P, O’Brien KL, Klugman KP (2016) Assessing the evidence for maternal pertussis immunization: a report from the Bill & Melinda Gates foundation symposium on pertussis infant disease burden in low- and lower-middle-income countries. Clin Infect Dis 63:S123–S133PubMedPubMedCentral
62.
Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ, Levin MJ, McElhaney JE, Poder A, Puig-Barbera J, Vesikari T, Watanabe D, Weckx L, Zahaf T, Heineman TC, Group ZOES (2015) Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 372:2087–2096PubMed
63.
Cunningham AL, Lal H, Kovac M et al (2016) Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med 375:1019–1032PubMed
64.
Jacobson RM, St Sauver JL, Finney Rutten LJ (2015) Vaccine hesitancy. Mayo Clin Proc 90:1562–1568PubMed
65.
Perry RT, Halsey NA (2004) The clinical significance of measles: a review. J Infect Dis 189:S4–S16PubMed
66.
Kaplan LJ, Daum RS, Smaron M, McCarthy CA (1992) Severe measles in immunocompromised patients. JAMA 267:1237–1241PubMed
67.
68.
Avota E, Gassert E, Schneider-Schaulies S (2010) Measles virus-induced immunosuppression: from effectors to mechanisms. Med Microbiol Immunol 199:227–237PubMed
69.
Slifka MK, Homann D, Tishon A, Pagarigan R, Oldstone MB (2003) Measles virus infection results in suppression of both innate and adaptive immune responses to secondary bacterial infection. J Clin Investig 111:805–810PubMedPubMedCentral
70.
71.
De Serres G, Gay NJ, Farrington CP (2000) Epidemiology of transmissible diseases after elimination. Am J Epidemiol 151:1039–1052PubMed
72.
Hens N, Abrams S, Santermans E, Theeten H, Goeyvaerts N, Lernout T, Leuridan E, Van Kerckhove K, Goossens H, Van Damme P, Beutels P (2015) Assessing the risk of measles resurgence in a highly vaccinated population: Belgium anno 2013. Euro Surveill 20:i20998
73.
Patel M, Lee AD, Redd SB, Clemmons NS, McNall RJ, Cohn AC, Gastanaduy PA (2019) Increase in measles cases—United States, January 1–April 26, 2019. MMWR Morb Mortal Wkly Rep 68:402–404PubMed
74.
Phadke VK, Bednarczyk RA, Salmon DA, Omer SB (2016) Association between vaccine refusal and vaccine-preventable diseases in the United States: a review of measles and pertussis. JAMA 315:1149–1158PubMedPubMedCentral
75.
Lo NC, Hotez PJ (2017) Public health and economic consequences of vaccine hesitancy for measles in the United States. JAMA Pediatr 171:887–892PubMedPubMedCentral
76.
Iizuka M, Nakagomi O, Chiba M, Ueda S, Masamune O (1995) Absence of measles virus in Crohn’s disease. Lancet 345:199PubMed
77.
Taylor B, Miller E, Lingam R, Andrews N, Simmons A, Stowe J (2002) Measles, mumps, and rubella vaccination and bowel problems or developmental regression in children with autism: population study. BMJ 324:393–396PubMedPubMedCentral
78.
Deer B (2011) How the case against the MMR vaccine was fixed. BMJ 342:c5347PubMed
79.
Editors of The Lancet (2010) Retraction: ileal lymphoid nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 375:445
80.
Strebel PM, Papania MJ, Gastañaduy PA, Goodson JL (2018) Measles vaccines. In: Plotkin SA, Orenstein WA, Offit PA, Edwards KM (eds) Plotkin’s vaccines. Elsevier, Philadelphia, pp 579–618
81.
Bresee J, Fry AM, Sambhara S, Cox NJ (2018) Inactivated influenza vaccines. In: Plotkin SA, Orenstein WA, Offit PA, Edwards KM (eds) Plotkin’s vaccines. Elsevier, Philadelphia, pp 456–488
82.
World Health Organization (2019) Global influenza strategy 2019–2030. World Health Organization, Geneva
83.
Jenkin DC, Mahgoub H, Morales KF, Lambach P, Nguyen-Van-Tam JS (2019) A rapid evidence appraisal of influenza vaccination in health workers: an important policy in an area of imperfect evidence. Vaccine X 2:100036PubMedPubMedCentral
84.
Dini G, Toletone A, Sticchi L, Orsi A, Bragazzi NL, Durando P (2018) Influenza vaccination in healthcare workers: a comprehensive critical appraisal of the literature. Hum Vaccines Immunother 14:772–789
85.
To KW, Lai A, Lee KC, Koh D, Lee SS (2016) Increasing the coverage of influenza vaccination in healthcare workers: review of challenges and solutions. J Hosp Infect 94:133–142PubMed
86.
Miles M, Ryman TK, Dietz V, Zell E, Luman ET (2013) Validity of vaccination cards and parental recall to estimate vaccination coverage: a systematic review of the literature. Vaccine 31:1560–1568PubMed
87.
Gagneur A, Pinquier D, Quach C (2015) Immunization of preterm infants. Hum Vaccines Immunother 11:2556–2563
88.
Sisson H, Gardiner E, Watson R (2017) Vaccination timeliness in preterm infants: an integrative review of the literature. J Clin Nurs 26:4094–4104PubMed
89.
Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, Bousvaros A, Dhanireddy S, Sung L, Keyserling H, Kang I (2014) 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 58:309–318PubMed
90.
Hotchkiss RS, Monneret G, Payen D (2013) Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol 13:862–874PubMedPubMedCentral
91.
Francois B, Jeannet R, Daix T, Walton AH, Shotwell MS, Unsinger J, Monneret G, Rimmele T, Blood T, Morre M, Gregoire A, Mayo GA, Blood J, Durum SK, Sherwood ER, Hotchkiss RS (2018) Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial. JCI Insight 3:e98960PubMedCentral
92.
Jensen IJ, Sjaastad FV, Griffith TS, Badovinac VP (2018) Sepsis-induced T cell immunoparalysis: the ins and outs of impaired T cell immunity. J Immunol 200:1543–1553PubMed
93.
Sjaastad FV, Condotta SA, Kotov JA, Pape KA, Dail C, Danahy DB, Kucaba TA, Tygrett LT, Murphy KA, Cabrera-Perez J, Waldschmidt TJ, Badovinac VP, Griffith TS (2018) Polymicrobial sepsis chronic immunoparalysis is defined by diminished ag-specific T cell-dependent B cell responses. Front Immunol 9:2532PubMedPubMedCentral
94.
Bruse N, Leijte GP, Pickkers P, Kox M (2019) New frontiers in precision medicine for sepsis-induced immunoparalysis. Expert Rev Clin Immunol 15:251–263PubMed
95.
Murray CJ, Ortblad KF, Guinovart C et al (2014) Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 384:1005–1070PubMedPubMedCentral
96.
Lozano R, Naghavi M, Foreman K et al (2012) Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:2095–2128PubMed
97.
Pletz MW, Uebele J, Gotz K, Hagel S, Bekeredjian-Ding I (2016) Vaccines against major ICU pathogens: where do we stand? Curr Opin Crit Care 22:470–476PubMed
98.
Klugman KP, Black S (2018) Impact of existing vaccines in reducing antibiotic resistance: primary and secondary effects. Proc Natl Acad Sci USA 115:12896–12901PubMedPubMedCentral
99.
Bechini A, Boccalini S, Ninci A, Zanobini P, Sartor G, Bonaccorsi G, Grazzini M, Bonanni P (2019) Childhood vaccination coverage in Europe: impact of different public health policies. Expert Rev Vaccines 18:693–701PubMed
100.
Holzmann H, Wiedermann U (2019) Mandatory vaccination: suited to enhance vaccination coverage in Europe? Euro Surveill 24:1900376PubMedCentral
101.
Radetsky M (1999) Smallpox: a history of its rise and fall. Pediatr Infect Dis J 18:85–93PubMed
102.
Plotkin SA, Orenstein WA, Offit PA, Edwards KM (2018) Plotkin’s vaccines. Elsevier, Philadelphia
103.
Graves PM, Deeks JJ, Demicheli V, Jefferson T (2010) Vaccines for preventing cholera: killed whole cell or other subunit vaccines (injected). Cochrane Database Syst Rev 8:Cd000974
104.
Sinclair D, Abba K, Zaman K, Qadri F, Graves PM (2011) Oral vaccines for preventing cholera. Cochrane Database Syst Rev 3:Cd008603
105.
Milligan R, Paul M, Richardson M, Neuberger A (2018) Vaccines for preventing typhoid fever. Cochrane Database Syst Rev 5:Cd001261PubMed
106.
Edwards KM, Decker MD (2018) Pertussis vaccines. In: Plotkin SA, Orenstein WA, Offit PA, Edwards KM (eds) Plotkin’s vaccines. Elsevier, Philadelphia, pp 711–761
107.
Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC (1999) Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO global surveillance and monitoring project. JAMA 282:677–686PubMed
108.
Demicheli V, Jefferson T, Ferroni E, Rivetti A, Di Pietrantonj C (2018) Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2:Cd001269PubMed
109.
Demicheli V, Rivetti A, Debalini MG, Di Pietrantonj C (2012) Vaccines for measles, mumps and rubella in children. Cochrane Database Syst Rev 2:CD004407
110.
Rubin SA (2018) Mumps vaccines. In: Plotkin SA, Orenstein WA, Offit PA, Edwards KM (eds) Plotkin’s vaccines. Elsevier, Philadelphia, pp 663–688
111.
Klugman KP, Dagan R, Malley R, Whitney CG (2018) Pneumococcal conjugate vaccine and pneumococcal common protein vaccines. In: Plotkin SA, Orenstein WA, Offit PA, Edwards KM (eds) Plotkin’s vaccines. Elsevier, Philadelphia, pp 773–815
112.
Grabenstein JD, Musher DM (2018) Pneumococcal polysaccharide vaccines. In: Plotkin SA, Orenstein WA, Offit PA, Edwards KM (eds) Plotkin’s vaccines. Elsevier, Philadelphia, pp 816–840
113.
Harper DM, DeMars LR (2017) HPV vaccines—a review of the first decade. Gynecol Oncol 146:196–204PubMed
114.
Luckett R, Feldman S (2016) Impact of 2-, 4- and 9-valent HPV vaccines on morbidity and mortality from cervical cancer. Hum Vaccines Immunother 12:1332–1342
115.
Suresh S, Upton J, Green M, Pham-Huy A, Posfay-Barbe KM, Michaels MG, Top KA, Avitzur Y, Burton C, Chong PP, Danziger-Isakov L, Dipchand AI, Hebert D, Kumar D, Morris SK, Nalli N, Ng VL, Nicholas SK, Robinson JL, Solomon M, Tapiero B, Verma A, Walter JE, Allen UD (2019) Live vaccines after pediatric solid organ transplant: proceedings of a consensus meeting, 2018. Pediatr Transplant 23:e13571PubMed
116.
Centers for Disease Control and Prevention (1999) Impact of vaccines universally recommended for children—United States, 1990–1998. MMWR Morb Mortal Wkly Rep 48:243–248
117.
Centers for Disease Control and Prevention (1999) Summary of notifiable diseases, United States, 1998. MMWR Morb Mortal Wkly Rep 47:ii-92
118.
119.
Chen RT, Rastogi SC, Mullen JR, Hayes SW, Cochi SL, Donlon JA, Wassilak SG (1994) The vaccine adverse event reporting system (VAERS). Vaccine 12:542–550PubMed
Metadaten
Titel
Missed vaccinations and critical care admission: all you may wish to know or rediscover—a narrative review
verfasst von
Laure F. Pittet
Mohamed Abbas
Claire-Anne Siegrist
Didier Pittet
Publikationsdatum
26.11.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
Intensive Care Medicine / Ausgabe 2/2020
Print ISSN: 0342-4642
Elektronische ISSN: 1432-1238
DOI
https://doi.org/10.1007/s00134-019-05862-0

Weitere Artikel der Ausgabe 2/2020

Intensive Care Medicine 2/2020 Zur Ausgabe

Understanding the Disease

Critical care management of infectious meningitis and encephalitis

Understanding the Disease

Understanding resistance in enterococcal infections

Narrative Review

Treatment of Ebola-related critical illness

Editorial

The zero-VAP sophistry and controversies surrounding prevention of ventilator-associated pneumonia

Conference Reports and Expert Panel

Antimicrobial de-escalation in critically ill patients: a position statement from a task force of the European Society of Intensive Care Medicine (ESICM) and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Critically Ill Patients Study Group (ESGCIP)

Narrative Review

Management of HIV-infected patients in the intensive care unit

Neu im Fachgebiet AINS

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Ärztliche Empathie hilft gegen Rückenschmerzen

23.04.2024 Leitsymptom Rückenschmerzen Nachrichten

Personen mit chronischen Rückenschmerzen, die von einfühlsamen Ärzten und Ärztinnen betreut werden, berichten über weniger Beschwerden und eine bessere Lebensqualität.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

hier abonnieren
Bildnachweise